No registrations found.
ID
Source
Health condition
colorectal cancer, serrated polyposis syndrome
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Incidence of interval colorectal cancer during protocolled endoscopic surveillance of SPS patients
Secondary outcome
- Incidence and characteristics of polyps found during endoscopic surveillance of SPS patients
- The ratio of annual and biennial surveillance advise
- Incidence of conversion to preventive colorectal surgery
- Incidence of post-colonoscopy complications
Background summary
Serrated polyposis syndrome (SPS) is characterized by the presence of multiple colorectal serrated polyps and is associated with an increased colorectal cancer (CRC) risk. The prevalance of SPS is estimated to be 1:3000 which makes SPS more common than other polyposis syndromes such as FAP. Due to the risk of malignant polyp transformation, SPS patients undergo endscopic surveillance with removal of polyps or a surgical colonic resection. However, no uniform and adequately substantiated endoscopic management protocol exists regarding polyp removal and surveillance intervals. Earlier research from our research group showed that annual surveillance by experts is safe with regard to interval carcinomas. However annual surveillance could result in systematic overtreatment.
Aim:
To prospectively assess the efficacy, feasibility and safety of a new systemised endoscopic surveillance protocol in which colonoscopic findings will determine the following surveillance interval; one or two years.
Study objective
To prospectively assess the efficacy, feasibility and safety of a renewed systemised endoscopic surveillance protocol in large multicentre HPS cohort.
Study design
5 years
Intervention
Data are collected in prospective manner from patients during routine surveillance endoscopies with removal of all polyps > 3 mm and/or with a adenomatous aspect.
Inclusion criteria
HPS patients defined as:
> 5 HPs/SSA proximal to the sigmoid, of which 2 > 10 mm in diameter, or more than 20 HPs/SSAs distributed throughout the colon.
Exclusion criteria
Carriers of a germline mutation in the MutYH or APC gene and individuals who have undergone a total colonic resection.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4476 |
| NTR-old | NTR4609 |
| Other | METC AMC : 10.17.2005 |